Revolver Therapeutics is pleased to announce this new funding is from UK Innovation Science and Seed Fund (UKI2S), managed by Future Planet Capital, and from o2h Ventures to progress its transcription factor inhibitors.
These novel peptide inhibitors were discovered using Revolver’s proprietary Transcription Block Survival (TBS) assay platform technology, which was spun out of the University of Bath.
The Company is initially targeting childhood gliomas, for which there is no effective treatment, in collaboration with The Institute of Cancer Research. With this investment, Revolver is now also exploring applications for adult cancers.